DGAP-News

STADA Arzneimittel AG: STADA announces agenda for the Annual General Meeting 2016

DGAP-News: STADA Arzneimittel AG / Key word(s): AGM/EGM
STADA Arzneimittel AG: STADA announces agenda for the Annual General Meeting
2016

20.07.2016 / 15:12
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

- Dividend proposal: Euro 0.70 per share

- New election of four shareholder representatives as Supervisory Board
candidates

- Remuneration system for the Executive Board reviewed and adjusted

- Restricted transferability of registered shares to be canceled

- Selection process for 2017 annual auditor planned

Bad Vilbel, July 20, 2016 - STADA Arzneimittel AG released the invitation
and agenda to its regular Annual General Meeting 2016 today. At the meeting
to be held on August 26, 2016, in the Congress Center Messe Frankfurt in
Frankfurt am Main, the Supervisory Board and Executive Board will propose
to the Annual General Meeting to approve a dividend of Euro 0.70 per share,
among other things. This would represent a 6 percent increase in the
dividend from last year, a total dividend payment of Euro 43.6 million
(previous year: Euro 40.0 million) and a distribution ratio of about 39
percent of reported net income.

The agenda also calls for the new election of four of the six shareholder
representatives to the company's Supervisory Board for five-year terms.
Supervisory Board members Dr. Eckhard Brüggemann, Dr. K. F. Arnold
Hertzsch, Dieter Koch and Constantin Meyer have resigned from their
positions as shareholder representatives effective at the end of the Annual
General Meeting on August 26, 2016. To ensure an orderly, transparent and
structured selection process for suitable successors in the interest of all
shareholders, STADA decided at the end of May to postpone the Annual
General Meeting.

Working on the basis of requirements profiles published on the company
website and with the assistance of the renowned personnel consulting
company Egon Zehnder, the Supervisory Board's Nomination Committee engaged
with four exceptional candidates who, in addition to their proven
international industry expertise, have shown themselves to be ideally
suited in personal terms for service on the Supervisory Board of STADA. The
Supervisory Board is confident that the following individuals ideally
complement the remaining shareholder representatives in the Supervisory
Board, Dr. Martin Abend and Ferdinand Oetker. They will work together with
the company's operational management team to lead STADA to a successful